The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …

Genomic studies have identified somatic alterations in the majority of myeloproliferative
neoplasms (MPN) patients, including JAK2 mutations in the majority of MPN patients and …

The current document is a revision of the International Working Group-Myeloproliferative
Neoplasms Research and Treatment (IWG-MRT) criteria for treatment response in …

Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN)
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …

There is growing appreciation that hematopoietic alterations underpin the ubiquitous
detrimental effects of metabolic disorders. The susceptibility of bone marrow (BM) …

Recently reported mature survival data have confirmed the favorable prognosis in
polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger …

Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their
cognate receptors that result in activation of intracellular signaling pathways. Alterations in …

Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …

Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia,
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …